TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors

Toshiyuki Toko, Yoshikazu Sugimoto, Ken Ichi Matsuo, Ryouko Yamasaki, Setsuo Takeda, Konstanty Wierzba, Tetsuji Asao, Yuji Yamada

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The antiestrogenic action of TAT-59 {(E)-4-[1-[4-[2-(dimethylamino)ethoxy]-phenyl]-2-(4-isopropyl)phenyl-1-butenyl] phenyl monophosphate} was characterized and compared with that of Tamoxifen (TAM). Its active metabolite, 4-OH-TAT-59, had a high binding affinity to estrogen receptor (ER), present in the cytosol of the uterus of immature rat, similar to estradiol. TAT-59 and 4-OH-TAT-59 inhibited in vitro estrogen-stimulated proliferation of MCF-7 cells at a lower concentration than TAM. In the absence of estradiol, TAT-59 and 4-OH-TAT-59 were effective at a lower concentration than that of 4-OH-Tamoxifen (4-OH-TAM), the active metabolite of TAM. In uterine growth inhibition, the effective dose of TAT-59 was about 3-6-fold lower than that of TAM, in various administration schedules. The minimum effective dose of TAT-59 against in vivo MCF-7 cells was about 3-fold lower than that of TAM. In DMBA-induced rat mammary tumors, TAT-59 inhibited the growth of existing tumors at about a 10-fold lower dose than TAM. Especially in the tumors with low ER levels (10-20 fmol/mg protein), TAT-59 showed a significantly stronger inhibitory effect than TAM. These experiments showed that TAT-59 was more effective in lower doses than TAM, even against the tumors with low ER content.

Original languageEnglish
Pages (from-to)397-404
Number of pages8
JournalEuropean Journal of Cancer and Clinical Oncology
Volume26
Issue number3
DOIs
Publication statusPublished - 1990
Externally publishedYes

Fingerprint

Tamoxifen
Hormones
Neoplasms
Estrogen Receptors
MCF-7 Cells
TAT 59
triphenylethylene
Estradiol
9,10-Dimethyl-1,2-benzanthracene
Growth
Cytosol
Uterus
Appointments and Schedules
Estrogens
hydroxide ion
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. / Toko, Toshiyuki; Sugimoto, Yoshikazu; Matsuo, Ken Ichi; Yamasaki, Ryouko; Takeda, Setsuo; Wierzba, Konstanty; Asao, Tetsuji; Yamada, Yuji.

In: European Journal of Cancer and Clinical Oncology, Vol. 26, No. 3, 1990, p. 397-404.

Research output: Contribution to journalArticle

Toko, Toshiyuki ; Sugimoto, Yoshikazu ; Matsuo, Ken Ichi ; Yamasaki, Ryouko ; Takeda, Setsuo ; Wierzba, Konstanty ; Asao, Tetsuji ; Yamada, Yuji. / TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. In: European Journal of Cancer and Clinical Oncology. 1990 ; Vol. 26, No. 3. pp. 397-404.
@article{35f580f725d142389e0f6bffb777570f,
title = "TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors",
abstract = "The antiestrogenic action of TAT-59 {(E)-4-[1-[4-[2-(dimethylamino)ethoxy]-phenyl]-2-(4-isopropyl)phenyl-1-butenyl] phenyl monophosphate} was characterized and compared with that of Tamoxifen (TAM). Its active metabolite, 4-OH-TAT-59, had a high binding affinity to estrogen receptor (ER), present in the cytosol of the uterus of immature rat, similar to estradiol. TAT-59 and 4-OH-TAT-59 inhibited in vitro estrogen-stimulated proliferation of MCF-7 cells at a lower concentration than TAM. In the absence of estradiol, TAT-59 and 4-OH-TAT-59 were effective at a lower concentration than that of 4-OH-Tamoxifen (4-OH-TAM), the active metabolite of TAM. In uterine growth inhibition, the effective dose of TAT-59 was about 3-6-fold lower than that of TAM, in various administration schedules. The minimum effective dose of TAT-59 against in vivo MCF-7 cells was about 3-fold lower than that of TAM. In DMBA-induced rat mammary tumors, TAT-59 inhibited the growth of existing tumors at about a 10-fold lower dose than TAM. Especially in the tumors with low ER levels (10-20 fmol/mg protein), TAT-59 showed a significantly stronger inhibitory effect than TAM. These experiments showed that TAT-59 was more effective in lower doses than TAM, even against the tumors with low ER content.",
author = "Toshiyuki Toko and Yoshikazu Sugimoto and Matsuo, {Ken Ichi} and Ryouko Yamasaki and Setsuo Takeda and Konstanty Wierzba and Tetsuji Asao and Yuji Yamada",
year = "1990",
doi = "10.1016/0277-5379(90)90241-K",
language = "English",
volume = "26",
pages = "397--404",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "3",

}

TY - JOUR

T1 - TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors

AU - Toko, Toshiyuki

AU - Sugimoto, Yoshikazu

AU - Matsuo, Ken Ichi

AU - Yamasaki, Ryouko

AU - Takeda, Setsuo

AU - Wierzba, Konstanty

AU - Asao, Tetsuji

AU - Yamada, Yuji

PY - 1990

Y1 - 1990

N2 - The antiestrogenic action of TAT-59 {(E)-4-[1-[4-[2-(dimethylamino)ethoxy]-phenyl]-2-(4-isopropyl)phenyl-1-butenyl] phenyl monophosphate} was characterized and compared with that of Tamoxifen (TAM). Its active metabolite, 4-OH-TAT-59, had a high binding affinity to estrogen receptor (ER), present in the cytosol of the uterus of immature rat, similar to estradiol. TAT-59 and 4-OH-TAT-59 inhibited in vitro estrogen-stimulated proliferation of MCF-7 cells at a lower concentration than TAM. In the absence of estradiol, TAT-59 and 4-OH-TAT-59 were effective at a lower concentration than that of 4-OH-Tamoxifen (4-OH-TAM), the active metabolite of TAM. In uterine growth inhibition, the effective dose of TAT-59 was about 3-6-fold lower than that of TAM, in various administration schedules. The minimum effective dose of TAT-59 against in vivo MCF-7 cells was about 3-fold lower than that of TAM. In DMBA-induced rat mammary tumors, TAT-59 inhibited the growth of existing tumors at about a 10-fold lower dose than TAM. Especially in the tumors with low ER levels (10-20 fmol/mg protein), TAT-59 showed a significantly stronger inhibitory effect than TAM. These experiments showed that TAT-59 was more effective in lower doses than TAM, even against the tumors with low ER content.

AB - The antiestrogenic action of TAT-59 {(E)-4-[1-[4-[2-(dimethylamino)ethoxy]-phenyl]-2-(4-isopropyl)phenyl-1-butenyl] phenyl monophosphate} was characterized and compared with that of Tamoxifen (TAM). Its active metabolite, 4-OH-TAT-59, had a high binding affinity to estrogen receptor (ER), present in the cytosol of the uterus of immature rat, similar to estradiol. TAT-59 and 4-OH-TAT-59 inhibited in vitro estrogen-stimulated proliferation of MCF-7 cells at a lower concentration than TAM. In the absence of estradiol, TAT-59 and 4-OH-TAT-59 were effective at a lower concentration than that of 4-OH-Tamoxifen (4-OH-TAM), the active metabolite of TAM. In uterine growth inhibition, the effective dose of TAT-59 was about 3-6-fold lower than that of TAM, in various administration schedules. The minimum effective dose of TAT-59 against in vivo MCF-7 cells was about 3-fold lower than that of TAM. In DMBA-induced rat mammary tumors, TAT-59 inhibited the growth of existing tumors at about a 10-fold lower dose than TAM. Especially in the tumors with low ER levels (10-20 fmol/mg protein), TAT-59 showed a significantly stronger inhibitory effect than TAM. These experiments showed that TAT-59 was more effective in lower doses than TAM, even against the tumors with low ER content.

UR - http://www.scopus.com/inward/record.url?scp=0025361621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025361621&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(90)90241-K

DO - 10.1016/0277-5379(90)90241-K

M3 - Article

VL - 26

SP - 397

EP - 404

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 3

ER -